Skip to main content
Reimbursement strategy

Identify reimbursement, payer and HTA barriers and define practical next steps.

Identify reimbursement, payer and HTA barriers and define practical next steps.

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Ongoing HTAs by the Swedish SBU as of September 2026

The Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)  is a government authority that conducts independent evaluations of methods and interventions used in healthcare, dental care, and social services. In addition, it reviews research related to functional status and disability, as well as the role of the work environment in the development of disease.

As of September 2026, the SBU is working on 23 projects, including the following health technology assessments related to MedTech:

  • Diagnostics for suspected endometriosis. The aim is to identify and assess systematic reviews of diagnostic approaches, including high-resolution transvaginal ultrasound and emerging methods such as liquid biopsy biomarkers in saliva or blood, as well as artificial intelligence and machine-learning approaches. Publication is expected in the second quarter of 2027;
  • Newborn screening for mucopolysaccharidosis type 1 (MPS-1). SBU is assessing the reliability of the MPS-1 test within the national newborn screening program. Publication is expected in the third quarter of 2026;
  • Diagnostic accuracy of different index tests for the diagnosis of food allergies. The assessment considers the sensitivity and specificity of different diagnostic tests for suspected food allergies. Publication is expected in the third quarter of 2026;
  • Diagnostic accuracy of different index tests for suspected peanut allergies. The assessment will compare the diagnostic accuracy of specific IgE based on whole-peanut extract, skin prick testing, and component testing for Ara h 1, Ara h 2, Ara h 3, and Ara h 8 in children and adults. Publication is expected in the second quarter of 2027;

This news is just one of about 300 market access news and updates collected by our team in the premium subscription service MTRC Access Intelligence every week from more than 80 organizations. Access our paid service to stay on top of all developments, specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, six-week, no-obligation trial.